Brad Vale, PhD, DVM

Dr. Brad Vale is a founder and general partner of Treo Ventures, a Silicon Valley- and Ireland-based medical device and healthcare IT venture fund. Dr. Vale was a Vice President at Johnson & Johnson Development Corporation (JJDC) starting in 1992 and in 2012 was named Head of JJDC. Dr. Vale’s investments focused mainly on biotech and medical device companies with an emphasis on implantable medical devices. He joined JNJ at Ethicon R&D, moved into the Corporate Science & Technology Office before joining JJDC in 1992, and in 1997 moved to California to establish its Silicon Valley office. He invested in over 30 companies for JJDC, including five that were ultimately acquired by various J&J subsidiaries. Dr. Vale has extensive experience in medical device research and development, including blood-compatible polymers, lasers, microsurgery, novel tissue closure, and hyaluronic acid for adhesion prevention. Dr. Vale has served as a director for many biotech and medtech companies, including Neuropace, CVRx, Nevro, USGI, GI Dynamics, Onehealthbank.com, and Atrionix. Dr. Vale has published in the area of medical device development and laser surgery. He holds a PhD in Biomedical Engineering from Iowa State University and a Doctor of Veterinary Medicine (DVM) from Washington State University. He completed his BS in Chemistry and Biology at Beloit College in Wisconsin.  He currently sits on the boards of Nevro (NYSE: NVRO), Hyalex, Shiratronics, Intuity, Agilvax, and Tramway Ventures.